Study guide

2.2 Tachyarrhythmias, Bradyarrhythmias & Channelopathies

MRCPI in General Medicine Part I Written

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Strategy & Foundation

1.1 MRCPI Part I Format, Scoring & Standard-Setting 1.2 RCPI BST Curriculum & Single-Best-Answer Exam Strategy

2 Chapter 2: Cardiology & Vascular Medicine

2.1 Acute Coronary Syndromes & Stable Angina 2.2 Tachyarrhythmias, Bradyarrhythmias & Channelopathies 2.3 Heart Failure & Valvular Heart Disease 2.4 Hypertension, Vascular & Pericardial Diseases

3 Chapter 3: Respiratory Medicine

3.1 Asthma, COPD & Airway Diseases 3.2 Pneumonia, Tuberculosis & Respiratory Infections 3.3 Interstitial Lung Disease & Pleural Disorders 3.4 Pulmonary Embolism, Pulmonary Hypertension & Sleep Apnoea

4 Chapter 4: Gastroenterology & Hepatology

4.1 Upper & Lower GI Disorders & Inflammatory Bowel Disease 4.2 Acute & Chronic Liver Disease 4.3 Pancreatitis, Biliary Tract & GI Bleeding 4.4 Malabsorption, GI Motility & Clinical Nutrition

5 Chapter 5: Nephrology & Acid-Base Disorders

5.1 Acute Kidney Injury & Glomerular Diseases 5.2 Chronic Kidney Disease & Renal Replacement Therapy 5.3 Electrolyte Imbalances & Acid-Base Disorders

6 Chapter 6: Endocrinology & Diabetes

6.1 Diabetes Mellitus & Metabolic Complications 6.2 Thyroid & Calcium Disorders 6.3 Adrenal, Pituitary & Endocrine Syndromes

7 Chapter 7: Rheumatology & Clinical Immunology

7.1 Inflammatory Arthritides 7.2 Systemic Autoimmune & Vasculitic Diseases 7.3 Metabolic Bone Disease & Clinical Immunology

8 Chapter 8: Haematology & Medical Oncology

8.1 Anaemias, Haemostasis & Thrombosis 8.2 Leukaemias, Lymphomas & Plasma Cell Disorders 8.3 Medical Oncology & Oncological Emergencies

9 Chapter 9: Neurology & Dermatology

9.1 Stroke & Cerebrovascular Diseases 9.2 Epilepsy, Headache & Movement Disorders 9.3 Neuromuscular & Peripheral Nerve Disorders 9.4 Cutaneous Manifestations of Systemic Disease

10 Chapter 10: Acute Medicine, Critical Care & Geriatrics

10.1 Acute Poisoning & Toxidromes 10.2 Sepsis, Shock & Resuscitation 10.3 Geriatric Syndromes, Frailty & Comprehensive Care

11 Chapter 11: Clinical Pharmacology & Therapeutics

11.1 Pharmacokinetics & Pharmacodynamics 11.2 High-Risk Drug Classes & Prescribing Safety 11.3 Adverse Drug Reactions & Drug Safety

12 Chapter 12: Basic Sciences, Biostatistics & Clinical Ethics

12.1 Applied Cardiovascular & Respiratory Physiology 12.2 Clinical Biochemistry, Molecular Genetics & Microbiology 12.3 Biostatistics, Evidence-Based Medicine & Ethics

2.2 Tachyarrhythmias, Bradyarrhythmias & Channelopathies

Key Takeaways Explain This Topic AI

In hemodynamically unstable tachyarrhythmias, immediate synchronized DC cardioversion (up to 3 shocks starting at 120-150 J biphasic) is mandatory regardless of QRS complex width.

Oral anticoagulation with a NOAC (Apixaban, Dabigatran, Edoxaban, or Rivaroxaban) is indicated in atrial fibrillation for stroke prevention when CHA2DS2-VASc score is >=1 in men or >=2 in women.

Rapid intravenous Adenosine (6 mg initial push, followed by 12 mg, then 12 mg if required) is first-line acute therapy for stable regular narrow-complex tachycardia (AVNRT/AVRT).

Type 1 Brugada syndrome ECG pattern (spontaneous or drug-induced coved ST elevation >=2 mm in V1-V2 followed by a negative T wave) combined with symptoms or family history warrants Implantable Cardioverter-Defibrillator (ICD) implantation for primary/secondary prevention of sudden cardiac death.

Last updated: July 2026

2.2 Tachyarrhythmias, Bradyarrhythmias & Channelopathies

Cardiac electrophysiology represents a core domain of MRCPI Part I. Clinical competence requires systematic ECG interpretation, rapid differentiation of narrow versus wide complex tachycardias, evidence-based management of atrial fibrillation, clear criteria for cardiac pacing, and accurate identification of inherited channelopathies that predispose to sudden cardiac death (SCD).

Approach to Tachyarrhythmias

The immediate clinical priority in any tachyarrhythmia is assessing hemodynamic stability :

Adverse Features : Hypotension (systolic BP <90 mmHg), acute heart failure, syncope, or active myocardial ischemia.

If Adverse Features Present : Immediate Synchronized DC Cardioversion under conscious sedation. Start at 120–150 J biphasic for atrial fibrillation/wide complex tachycardia, or 70–120 J for atrial flutter/SVT.

If Hemodynamically Stable : Differentiate based on QRS width (<120 ms vs >=120 ms) and regularity.

  • Narrow QRS Tachycardias (<120 ms)
  • 1. Regular Narrow Complex Tachycardia

Atrioventricular Nodal Re-entrant Tachycardia (AVNRT) : Accounts for 60% of SVTs. Caused by functional re-entry within the AV node utilizing a slow anterograde pathway and fast retrograde pathway. P waves are buried within or immediately follow the QRS complex (pseudo-R' in V1, pseudo-S in II/III/aVF).

Atrioventricular Re-entrant Tachycardia (AVRT) : Re-entry utilizing an anatomical accessory pathway (e.g., Bundle of Kent in Wolff-Parkinson-White syndrome). Orthodromic AVRT conducts anterograde via the AV node and retrograde via the pathway (narrow QRS).

Acute Management Algorithm :

Vagal Maneuvers : Modified Valsalva maneuver (strain for 15 seconds followed by passive leg raise) converts ~43% of SVTs.

Intravenous Adenosine : Purinergic A1 receptor agonist causing transient AV nodal block. Dose: 6 mg rapid IV push into a large peripheral vein followed by a 20 mL saline flush. If unconverted within 1–2 minutes, administer 12 mg , followed by a second 12 mg dose if required.

Second-line Agents : Intravenous Verapamil (2.5–5 mg over 2 minutes) or Bisoprolol if adenosine fails or is contraindicated (e.g., severe asthma).

2. Irregular Narrow Complex Tachycardia

Atrial Fibrillation (AF) : Absence of P waves with irregular ventricular response.

Atrial Flutter with Variable Block : Sawtooth flutter waves (leads II, III, aVF) at an atrial rate of 250–350 bpm with variable AV conduction.

Multifocal Atrial Tachycardia (MAT) : >=3 distinct P-wave morphologies with variable PR intervals, typically seen in severe COPD or exacerbations of pulmonary disease. Treated by correcting underlying hypoxia/hypercapnia and IV Diltiazem/Verapamil (avoid beta-blockers in severe bronchospasm).

Wide QRS Tachycardias (>=120 ms)

Broad-complex tachycardia must be managed as Ventricular Tachycardia (VT) until proven otherwise (80–90% of cases). Differentiation from SVT with aberrant conduction (bundle branch block) is critical.

ECG Criteria Favoring VT (Brugada Criteria)

Absence of RS Complex in all precordial leads (V1–V6, regular concordant pattern).

RS Interval >100 ms in any precordial lead.

Atrioventricular Dissociation : P waves marching independently through QRS complexes, Capture beats (normal narrow QRS), or Fusion beats (hybrid QRS).

Morphology Criteria : QRS width >140 ms (LBBB-like) or >160 ms (RBBB-like), QR or monophasic R wave in V1.

Polymorphic VT & Torsades de Pointes

Torsades de Pointes is a specific form of polymorphic VT occurring in the context of QT prolongation (congenital or acquired secondary to hypokalemia, hypomagnesemia, or drugs like sotalol, erythromycin, haloperidol).

Acute Treatment : Intravenous Magnesium Sulfate 2 g push regardless of serum magnesium level, correction of electrolytes, and overdrive cardiac pacing or isoprenaline infusion to shorten the QTc.

Vaughan-Williams Classification of Antiarrhythmics

Class Mechanism of Action Clinical Examples Primary Indications

Ia Moderate Na+ block, prolongs Action Potential Duration (APD) Procainamide, Disopyramide, Quinidine WPW-mediated AF, ventricular arrhythmias

Ib Mild Na+ block, shortens APD Lidocaine, Mexiletine Ischemic ventricular tachycardia

Ic Marked Na+ block, no effect on APD Flecainide, Propafenone AF cardioversion ("pill-in-the-pocket"); Contraindicated in structural heart disease!

II Beta-adrenergic blockade Bisoprolol, Metoprolol, Esmolol Rate control in AF, post-MI mortality reduction

III K+ channel block, prolongs APD & QTc Amiodarone, Sotalol, Dronedarone VT, VF, refractory AF cardioversion/maintenance

IV Non-dihydropyridine Ca2+ channel block Verapamil, Diltiazem SVT termination, rate control in AF (contraindicated in HFrEF)

  • Atrial Fibrillation Management Strategy
  • 1. Stroke Risk & Anticoagulation (CHA2DS2-VASc Score)

Congestive HF (1 point), Hypertension (1 point), Age >=75 (2 points), Diabetes (1 point), Stroke/TIA/Thromboembolism (2 points), Vascular Disease (1 point), Age 65–74 (1 point), Sex Category (Female) (1 point).

Anticoagulation Threshold : Score >=1 in men or >=2 in women warrants Non-Vitamin K Antagonist Oral Anticoagulants ( NOACs : Apixaban 5 mg bd, Rivaroxaban 20 mg daily, Dabigatran 150 mg bd, Edoxaban 60 mg daily) over Warfarin due to superior safety profiles and reduced intracranial hemorrhage rates.

2. Rate vs. Rhythm Control

Rate Control : Target resting HR <110 bpm (lenient rate control per RACE II trial). First-line agents: Beta-blockers, Diltiazem/Verapamil, or Digoxin (especially in heart failure).

Rhythm Control : Indicated in symptomatic AF despite rate control, young patients, or early AF (EAST-AFNET 4 trial). Modalities include electrical cardioversion, antiarrhythmic drugs (Flecainide if no structural heart disease; Amiodarone if heart failure present), and Catheter Ablation (pulmonary vein isolation).

  • Bradyarrhythmias & Conduction System Disease
  • Classification of AV Block

First-Degree AV Block : PR interval >200 ms (>5 small squares), all P waves conducted.

Second-Degree AV Block - Mobitz Type I (Wenckebach) : Progressive PR lengthening until a P wave fails to conduct. Benign, nodal site of block, usually responsive to atropine.

Second-Degree AV Block - Mobitz Type II : Constant PR interval with intermittent unconducted P waves. Infra-Hisian block with high risk of progression to complete heart block.

Third-Degree (Complete) AV Block : Total AV dissociation. P-P and R-R intervals are regular, but completely independent.

Emergency Management & Pacing Indications

Acute Bradycardia Algorithm : Administer Atropine 500 mcg IV (repeat up to max 3 mg). If ineffective, initiate IV Isoprenaline or Adrenaline infusion, or proceed to Transcutaneous Pacing followed by transvenous wire placement.

Permanent Pacemaker (PPM) Indications : Mobitz Type II AV block, 3rd-degree complete heart block, symptomatic sinus node dysfunction (Sick Sinus Syndrome), or trifascicular block with prolonged HV interval.

Inherited Channelopathies

Long QT Syndrome (LQTS) : QTc >480 ms (Bazett's formula: Q T c = Q T / R R QT_c = QT / \sqrt{RR} Q T c ​ = QT / RR ​ ). Mutation in ion channels.

LQTS Type 1 (KCNQ1) : Triggers: Swimming, exercise. T-wave morphology: Broad-based.

LQTS Type 2 (KCNH2) : Triggers: Auditory stimuli (alarm clocks), emotional stress. T-wave morphology: Notched/bifid.

LQTS Type 3 (SCN5A) : Triggers: Rest, sleep. T-wave morphology: Late-appearing.

Management : Non-selective Beta-blockers (Nadolol or Propranolol), avoid QT-prolonging drugs, ICD for survivors of cardiac arrest.

Brugada Syndrome : Autosomal dominant mutation in SCN5A (cardiac sodium channel). Predominantly affects Southeast Asian males.

Type 1 Pattern : ST elevation >=2 mm in V1–V2 with coved appearance followed by negative T wave.

Diagnostic Provocation : Intravenous Ajmaline or Flecainide unmasks Type 1 pattern.

Management : ICD implantation is the only proven therapy for preventing SCD in high-risk patients; quinidine used for electrical storms.

Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) : Mutations in RYR2 (ryanodine receptor). Characterized by exercise/emotion-induced bidirectional VT in young patients with structurally normal hearts. Treated with high-dose Beta-blockers, Flecainide, and left cardiac sympathetic denervation.

Loading diagram... Tachycardia Emergency Resuscitation Algorithm